{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-010258","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2023-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.549534+00:00","generated_at":"2026-06-20T14:17:18.193645+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"TherapeuticsMD terminates employment agreement of CFO Michael Donegan; remains as consulting CFO","bullets":["CFO Michael Donegan's employment agreement terminated without 'Good Cause' effective Dec 30, 2022.","Separation benefits: 12-month base salary, 2022 target bonus, 24 months COBRA, full equity vesting.","Eligible for $135k in performance bonuses under 2022 ERB-Plan, including $67.5k for transition assistance.","Donegan continues as Principal Financial Officer and Principal Accounting Officer in consulting capacity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-010258","json":"https://secwatch.observer/filing/0001193125-23-010258.json","markdown":"https://secwatch.observer/filing/0001193125-23-010258.md","text":"https://secwatch.observer/filing/0001193125-23-010258.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000119312523010258/0001193125-23-010258-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000119312523010258/d399403d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T14:17:18.193645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea8e71a8e0","claim":"Michael Donegan was terminated as Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance at TherapeuticsMD, Inc..","evidence_excerpt":"Mr. Donegan is continuing to serve as the Company’s Principal Financial Officer and Principal Accounting Officer in a consulting capacity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000119312523010258/0001193125-23-010258-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}